Cell-ebrating the dosing of patients with jCell in a phase 2 clinical trial for RP
The latest research news from Retina UK.
Search results
The latest research news from Retina UK.
Dr Nikolas Pontikos is a Senior Research Fellow at UCL Institute of Ophthalmology, and has been working on inherited retinal conditions for several years.
This is the final edition of Look Forward this year and what a year it has been! We’ve had some very positive feedback about our Conferences and the Big Give Christmas Challenge is back - a great opportunity to double your donation at no extra cost to you! We’ve included a handy ‘What’s on’ article which outlines some of our plans for 2026. We would like to take this opportunity to wish all of our readers a very Merry Christmas and a happy and fulfilling New Year.
Our partnerships are mutually beneficial. For Retina UK this means we can fund more research and offer support on a local level, while our partners can achieve corporate social responsibility objectives whilst making a tangible impact.
We always aim to provide a high standard of service to our community. If you are unhappy with any of our services it is important that you let us know.
Biotechnology company MeiraGTx has announced encouraging news from its phase 1/2 clinical trial of botaretigene sparoparvovec (previously known as AAV-RPGR), a gene therapy aimed at X-linked retinitis pigmentosa caused by faults in the RPGR gene.
The latest research news from Retina UK.
SpliceBio has begun the dose-expansion portion of their phase 1/2 clinical trial of SB-007, a dual adeno-associated viral vector gene therapy for Stargardt disease.
You may have heard that a cell-based treatment approach (sometimes referred to as a “stem cell treatment”), developed by a company called ReNeuron, is being tested in a clinical trial at Oxford Eye Hospital and other centres in the US and Europe.
Join Lauren as she chats with Paula McGrath, Deputy CEO of Retina UK, about the 2025 Sight Loss Survey